Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib and Prednisone for Advanced Squamous NSCLC
NCT04497584Phase 2Active, not recruiting
- Sponsor
- UT Southwestern Medical Center
- Start
- Aug 2021
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of afatinib in non-small cell lung cancer, squamous cell carcinoma (NSCLC), sponsored by UT Southwestern Medical Center. Started Aug 2021; status: active, not recruiting.
02
Drugs
afatinib
03
Conditions
non-small cell lung cancer, squamous cell carcinoma (NSCLC)
Beyond the preview
Go deeper on NCT04497584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04497584.